MoonLake Immunotherapeutics
(NASDAQ) MLTX
MoonLake Immunotherapeutics Financials at a Glance
Market Cap
$1.25B
Revenue (TTM)
$0.00
Net Income (TTM)
$227.32M
EPS (TTM)
$-3.53
P/E Ratio
-4.92
Dividend
$0.00
Beta (Volatility)
0.54 (Low)
Dividend
$0.00
Beta (Volatility)
0.54 (Low)
Price
$17.35
Volume
1,687,062.887
Open
$16.29
Price
$17.35
Volume
1,687,062.887
Open
$16.29
Previous Close
$17.36
Daily Range
$16.02 - $17.53
52-Week Range
$5.95 - $62.75
Dividend
$0.00
Beta (Volatility)
0.54 (Low)
Price
$17.35
Volume
1,687,062.887
Open
$16.29
Previous Close
$17.36
Daily Range
$16.02 - $17.53
52-Week Range
$5.95 - $62.75
MLTX News
MLTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout MoonLake Immunotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
130
CEO
Jorge Santos da Silva, PhD
Website
www.moonlaketx.comHeadquarters
Zug, 6300, CH
MLTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-61%
Return on Capital
-65%
Return on Assets
-54%
Earnings Yield
-20.33%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.25B
Shares Outstanding
71.73M
Volume
1.69M
Short Interest
0.00%
Avg. Volume
2.01M
Financials (TTM)
Gross Profit
$2.62M
Operating Income
$244.83M
EBITDA
$219.85M
Operating Cash Flow
$196.01M
Capital Expenditure
$35.00K
Free Cash Flow
$196.04M
Cash & ST Invst.
$393.97M
Total Debt
$75.71M
MoonLake Immunotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$751.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.25B
N/A
Market Cap/Employee
$12.45M
N/A
Employees
100
N/A
Net Income
$62.43M
-36.9%
EBITDA
$60.02M
-24.3%
Quarterly Fundamentals
Net Cash
$318.26M
-28.5%
Accounts Receivable
$4.87M
+71.3%
Inventory
$0.00
N/A
Long Term Debt
$74.85M
+5035.0%
Short Term Debt
$1.23M
-10.1%
Return on Assets
-53.56%
N/A
Return on Invested Capital
-64.61%
N/A
Free Cash Flow
$58.79M
-20.9%
Operating Cash Flow
$58.79M
-21.3%